代谢组学在阿尔茨海默症病理机制和中药疗效评价研究中的应用进展

Application progress of metabolomics in pathological mechanism of Alzheimer’s disease and evaluation of efficacy of traditional Chinese medicine

阿尔茨海默病(Alzheimer’s disease,AD)是1种复杂的神经退行性疾病,研究表明其代谢改变与早期疾病机制有关。为扩大生物系统中代谢物检测的范围,基于多种分析平台联用的代谢组学策略,开发精确有效、侵入性小的生物标志物是AD代谢组学的研究热点,而空间代谢组学为生物组织代谢和药物代谢提供了全新视角。越来越多的中药单体、单味药材及中药复方被证明对AD具有一定的药效作用,从代谢组学角度探讨药效机制,可以提供潜在的生物标志物和代谢模式,有助于定量评价药物疗效及探索作用机制。本文综述了近5年代谢组学在AD病理机制和中药疗效评价研究中的应用进展。

Alzheimer’s disease(AD)is a complex neurodegenerative disease.Studies have shown that the metabolic changes of AD are associated to the early pathogenesis.To expand the scope of metabolite detection in biological system,the development of accurate,effective and less invasive biomarkers based on the combined metabolomics strategy of multiple analysis platforms are the research hotspot of AD metabolomics,and spatial metabolomics have provided new perspectives on biological tissue metabolism and drug metabolism.More and more traditional Chinese medicine monomers,single herbs and traditional Chinese medicine compounds were proved to have certain pharmacodynamic effects on AD.To explore the pharmacodynamic mechanism from the perspective of metabolomics could provide potential biomarkers and metabolic models,and help to quantitatively evaluate the efficacy of drugs and explore the mechanism of action.The application progresses on the metabolomics ofpathological mechanism of AD and efficacy evaluation of traditional Chinese medicine in recent five years is reviewed.